5月25日，据CDE官网消息，信达生物制药（苏州）有限公司联合申请药品“IBI363”，获得临床试验默示许可，受理号CXSL2500233。
公示信息显示，药品“IBI363”适应症：免疫治疗失败的晚期鳞状非小细胞肺癌。
信达生物制药（苏州）有限公司，成立于2011年，位于苏州市，是一家以从事医药制造业为主的企业。企业注册资本15946.475万美元，实缴资本15246.475万美元。
通过天眼查大数据分析，信达生物制药（苏州）有限公司共对外投资了4家企业，参与招投标项目473次，知识产权方面有商标信息868条，专利信息146条，此外企业还拥有行政许可68个。
主要股东信息显示，信达生物制药（苏州）有限公司由Innovent Biologics (HK) Limited持股99.0594%、Oriza Xinda International Limited持股0.9406%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.